Gadolinium Contrast Agent Approved for Supra-Aortic MRI Angiography
By MedImaging International staff writers Posted on 19 May 2016 |
A gadolinium-based contrast agents (GBCA) indicated for use with magnetic resonance angiography (MRA) has been approved for evaluating supra-aortic or renal artery disease.
Gadavist, a product of Bayer (Leverkusen, Germany) was previously indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients (including term neonates) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS). It is also indicated for use with MRI to assess the presence and extent of malignant breast disease.
In MRI, visualization of normal and pathological tissue depends on variations in the radiofrequency (RF) signal intensity that occurs with differences in proton density, differences of spin-lattice (longitudinal) relaxation times (T1), and differences in the spin-spin (transverse) relaxation time (T2). When placed in a magnetic field, Gadavist shortens the T1 and T2 relaxation times, depending on the concentration in the tissue, the field strength of the MRI system, and the relative ratio of the longitudinal and transverse relaxation times.
“Until now, no contrast agents were FDA-approved for use with MRA of the supra-aortic arteries,” said Elias Melhem, MD, chair of the department of diagnostic radiology & nuclear medicine at the University of Maryland, lead investigator for the Gadavist-Enhanced MRA of the Supra-Aortic Vessels (GEMSAV) study. “With FDA's action, radiologists now have an approved MRA contrast agent to help visualize supra-aortic arteries in patients with known or suspected supra-aortic arterial disease, including conditions such as prior stroke or transient ischemic attack.”
GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired drug elimination of the drugs. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears highest among patients with chronic, severe kidney disease or acute kidney injury (AKI).
Related Links:
Bayer
Gadavist, a product of Bayer (Leverkusen, Germany) was previously indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients (including term neonates) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS). It is also indicated for use with MRI to assess the presence and extent of malignant breast disease.
In MRI, visualization of normal and pathological tissue depends on variations in the radiofrequency (RF) signal intensity that occurs with differences in proton density, differences of spin-lattice (longitudinal) relaxation times (T1), and differences in the spin-spin (transverse) relaxation time (T2). When placed in a magnetic field, Gadavist shortens the T1 and T2 relaxation times, depending on the concentration in the tissue, the field strength of the MRI system, and the relative ratio of the longitudinal and transverse relaxation times.
“Until now, no contrast agents were FDA-approved for use with MRA of the supra-aortic arteries,” said Elias Melhem, MD, chair of the department of diagnostic radiology & nuclear medicine at the University of Maryland, lead investigator for the Gadavist-Enhanced MRA of the Supra-Aortic Vessels (GEMSAV) study. “With FDA's action, radiologists now have an approved MRA contrast agent to help visualize supra-aortic arteries in patients with known or suspected supra-aortic arterial disease, including conditions such as prior stroke or transient ischemic attack.”
GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired drug elimination of the drugs. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears highest among patients with chronic, severe kidney disease or acute kidney injury (AKI).
Related Links:
Bayer
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer